PRE Quote, Financials, Valuation and Earnings

HUTCHMED (China) has a net margin of -137.21% compared to Prenetics Global's net margin of --. Prenetics Global's return on equity of -23.16% beat HUTCHMED (China)'s return on equity of 4.99%.

Prenetics Global has a consensus price target of $13.00, signalling upside risk potential of 250.4%. On the other hand HUTCHMED (China) has an analysts' consensus of $26.43 which suggests that it could grow by 77.51%. Given that Prenetics Global has higher upside potential than HUTCHMED (China), analysts believe Prenetics Global is more attractive than HUTCHMED (China).

Prenetics Global has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison HUTCHMED (China) has a beta of 0.658, suggesting its less volatile than the S&P 500 by 34.171%.

Prenetics Global has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. HUTCHMED (China) offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Prenetics Global pays -- of its earnings as a dividend. HUTCHMED (China) pays out -- of its earnings as a dividend.

Prenetics Global quarterly revenues are $7.8M, which are larger than HUTCHMED (China) quarterly revenues of --. Prenetics Global's net income of -$10.7M is higher than HUTCHMED (China)'s net income of --. Notably, Prenetics Global's price-to-earnings ratio is -- while HUTCHMED (China)'s PE ratio is 74.45x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Prenetics Global is 1.79x versus 4.12x for HUTCHMED (China). Usually stocks with elevated PS ratios are considered overvalued.

Hong Kong Pharma Digital Technology Holdings has a net margin of -137.21% compared to Prenetics Global's net margin of --. Prenetics Global's return on equity of -23.16% beat Hong Kong Pharma Digital Technology Holdings's return on equity of --.

Prenetics Global has a consensus price target of $13.00, signalling upside risk potential of 250.4%. On the other hand Hong Kong Pharma Digital Technology Holdings has an analysts' consensus of -- which suggests that it could fall by --. Given that Prenetics Global has higher upside potential than Hong Kong Pharma Digital Technology Holdings, analysts believe Prenetics Global is more attractive than Hong Kong Pharma Digital Technology Holdings.

Prenetics Global has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Hong Kong Pharma Digital Technology Holdings has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Prenetics Global has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Hong Kong Pharma Digital Technology Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Prenetics Global pays -- of its earnings as a dividend. Hong Kong Pharma Digital Technology Holdings pays out -- of its earnings as a dividend.

Prenetics Global quarterly revenues are $7.8M, which are larger than Hong Kong Pharma Digital Technology Holdings quarterly revenues of --. Prenetics Global's net income of -$10.7M is higher than Hong Kong Pharma Digital Technology Holdings's net income of --. Notably, Prenetics Global's price-to-earnings ratio is -- while Hong Kong Pharma Digital Technology Holdings's PE ratio is 7.32x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Prenetics Global is 1.79x versus 0.67x for Hong Kong Pharma Digital Technology Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Regencell Bioscience Holdings has a net margin of -137.21% compared to Prenetics Global's net margin of --. Prenetics Global's return on equity of -23.16% beat Regencell Bioscience Holdings's return on equity of --.

Prenetics Global has a consensus price target of $13.00, signalling upside risk potential of 250.4%. On the other hand Regencell Bioscience Holdings has an analysts' consensus of -- which suggests that it could fall by --. Given that Prenetics Global has higher upside potential than Regencell Bioscience Holdings, analysts believe Prenetics Global is more attractive than Regencell Bioscience Holdings.

Prenetics Global has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Regencell Bioscience Holdings has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Prenetics Global has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regencell Bioscience Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Prenetics Global pays -- of its earnings as a dividend. Regencell Bioscience Holdings pays out -- of its earnings as a dividend.

Prenetics Global quarterly revenues are $7.8M, which are larger than Regencell Bioscience Holdings quarterly revenues of --. Prenetics Global's net income of -$10.7M is higher than Regencell Bioscience Holdings's net income of --. Notably, Prenetics Global's price-to-earnings ratio is -- while Regencell Bioscience Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Prenetics Global is 1.79x versus -- for Regencell Bioscience Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Sino Biopharmaceutical has a net margin of -137.21% compared to Prenetics Global's net margin of --. Prenetics Global's return on equity of -23.16% beat Sino Biopharmaceutical's return on equity of 8.57%.

Prenetics Global has a consensus price target of $13.00, signalling upside risk potential of 250.4%. On the other hand Sino Biopharmaceutical has an analysts' consensus of -- which suggests that it could fall by --. Given that Prenetics Global has higher upside potential than Sino Biopharmaceutical, analysts believe Prenetics Global is more attractive than Sino Biopharmaceutical.

Prenetics Global has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Sino Biopharmaceutical has a beta of 0.536, suggesting its less volatile than the S&P 500 by 46.434%.

Prenetics Global has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sino Biopharmaceutical offers a yield of 2.19% to investors and pays a quarterly dividend of $0.00 per share. Prenetics Global pays -- of its earnings as a dividend. Sino Biopharmaceutical pays out -- of its earnings as a dividend.

Prenetics Global quarterly revenues are $7.8M, which are larger than Sino Biopharmaceutical quarterly revenues of --. Prenetics Global's net income of -$10.7M is higher than Sino Biopharmaceutical's net income of --. Notably, Prenetics Global's price-to-earnings ratio is -- while Sino Biopharmaceutical's PE ratio is 17.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Prenetics Global is 1.79x versus 2.13x for Sino Biopharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.